Human papillomaviruses (HPVs) infect the squamous epithelium, and cause skin warts, genital warts and cancers, including uterine cervical cancer. Amongst the enormously diverse types of HPVs, HPV16 and HPV18 are most prevalent and responsible for approximately 70% of cervical cancer cases. Current preventive HPV vaccines contain virus-like particles which are composed of L1 major capsid proteins of HPV16 and HPV18. Although bivalent and quadrivalent vaccines exhibit excellent preventive efficacy and safety, they have several limitations. First, since the protection against HPV is type-restricted, the remaining 30% of cervical cancers and warts cannot be prevented. Second, due to the absence of therapeutic activity in the vaccines, people already infected by the HPVs cannot benefit from the current vaccines. Therefore, new preventive and therapeutic vaccines are required for better control of HPV-associated diseases. New developments include a novel nonavalent preventive vaccine that contains five additional cancer-associated HPV types, and it has been tested and approved in 2014. Recently, several groups reported promising clinical results with novel therapeutic HPV vaccines. This review provides an overview of the success of current preventive vaccines and perspectives on the next-generation HPV vaccines.
I. INTRODUCTION
Human papillomaviruses (HPVs) are DNA viruses that infect and replicate in the squamous epithelium of skin and mucous membranes. HPVs are etiologically linked to benign and malignant diseases of skin and mucosal epithelia, such as skin warts, genital warts and anogenital cancers. Of the 12,700,000 new cancers that occurred in 2008 worldwide, 610,000 cases (4.8%) were attributable to HPV infection (1, 2) . Notably, almost every uterine cervical cancer is caused by HPV infection, and it is the third leading cause of female cancer deaths in less developed countries (3) 
II. HPV and HPV-associated Diseases
HPVs are non-enveloped capsid viruses that have doublestranded circular DNA genomes. The icosahedral capsid encloses an approximately 8 kbp genome that encodes six early proteins (E1, E2, E4, E5, E6 and E7) and two late structural proteins (L1 and L2) (4) . Among them, E6, E7, L1 and L2 proteins are important with regards to carcinogenesis and vaccine development. E6 and E7 are HPV oncoproteins which inhibit activities of the tumor suppressor genes P53 and RB, respectively, and L1 and L2 are major and minor capsid proteins, respectively (4) . The icosahedral capsid of HPV is composed of 72 capsomeres which consist of an L1 pentamer and an L2 monomer. These two structural proteins are major targets of vaccines for developing neutralizing antibodies.
There are more than 200 types of HPVs (5) However, persistent infection with high-risk HPV types may cause the development of cancers. Those are uterine cervical, penile, vaginal, vulvar, anal, and oropharyngeal cancers. Especially, uterine cervical cancer is the third most common female malignancy worldwide, and is responsible for 275,000 deaths annually (1) . HPV infection often causes low-grade cervical dysplasia: cervical intraepithelial neoplasia (CIN) 1, which usually clears spontaneously (60% of cases) and rarely progresses to cervical cancer (1%).
However, persistent infection with high-risk HPV types can cause high-grade cervical dysplasia (CIN 2, 3) , where a lower percentage of high-grade lesions spontaneously clear (40% and 33% for CIN 2 and 3, respectively), and a greater proportion progress to invasive cervical cancer if left untreated (5% and >12% for CIN 2 and 3, respectively) (9~11). Infection with HPVs is considered as a prerequisite for uterine cervical cancer (12) , and almost all cases are attributable to high-risk HPV types (13) . Moreover, HPV infection is etiologically associated with 88% of anal cancers, 70% of vaginal cancers, 43% of vulvar cancers, 50% of penile cancers, and 13~56% of oropharyngeal cancers (1).
Low-risk mucosal HPVs induce genital warts (condyloma acuminatum), which are benign hyperproliferative lesions.
Anogenital warts are one of the most common sexually transmitted diseases. In a systematic review, the worldwide annual incidence of anogenital warts ranged from 160 to 289 per 100,000 persons (14) . More than 90% of genital warts are caused by HPV6 and HPV11 (Table 1) . Genital warts are generally benign and resolve within 6 months.
However, about 30% of genital warts recur, which can result in lengthy, expensive, painful treatments, and substantial psychological burden (9) .
Cutaneous HPVs induce skin warts, benign tumors of the cutaneous epithelia. Nineteen HPV types are frequently found in skin warts, with HPV1 being most prevalent, followed by HPV27, HPV57 and HPV2 (15) ( Table 1) . Skin warts are common in children, but they may also constitute (16, 17) . Similar to genital warts, treatment for skin warts can be lengthy, expensive, and painful, and recurrence is common. antibodies in the protection (20, 27, 28) . In clinical trials of the two vaccines, the vaccine-induced antibody levels are substantially higher than the antibody levels induced by natural HPV infection (29, 30) . Furthermore, the protection efficacy did not wane for several years. In a long-term follow-up study for 113 months (9.4 years), all bivalentvaccinated people sustained HPV16/18-specific serum antibody levels several-fold higher than natural infection levels 
III. Current Preventive Vaccines

Limitations of current preventive HPV vaccines
As reviewed above, the current quadrivalent and bivalent 
IV. Next-generation Preventive Vaccines with Extended Coverage of HPV Types
As mentioned previously, the current bivalent and quadri- 
